Mesna reacts with acrolein and other urotoxic metabolites of oxazaphosphorines

(cyclophosphamide or ifosfamide) to form stable, non-urotoxic compounds. Mesna

does not have any antitumour activity, nor does it appear to interfere with the

antitumour activity of antineoplastic medicine. This medication is used to protect the

bladder wall from the harmful effects of some cancer-fighting medicine.